Boehringer Ingelheim Foundation supports research of Dr. Peng Wu
Dr. Peng Wu receives 90.000 Euros from the Boehringer Ingelheim Foundation for his research on the degradation of mRNA
Dr. Peng Wu is an independent group leader at the CGC since 2018. His research work focuses on the development of novel small molecule-based chemical modulators to manipulate pervasive protein-RNA interactions. With his new project he aims to target the RNA-binding proteins that recognize the mRNA modifications for the identification of small-molecule inhibitors and activators. Such small molecules will be evaluated as potential hits for tools to probe the regulatory network involving these RNA-binding proteins that mediate mRNA-degradation and as hits for therapeutics for the treatment of human diseases such as in neurological disorders and viral infections that are associated with dysregulation of such RNA-binding proteins.
About the Boehringer Ingelheim Foundation
The Boehringer Ingelheim Foundation is a legally independent, non-profit foundation committed to the promotion of the medical, biological, chemical, and pharmaceutical sciences. It was established in 1977 by Hubertus Liebrecht, a member of the shareholder family of the Boehringer Ingelheim company. With the Perspectives Programme Plus 3 and its Exploration Grants, the foundation supports independent junior group leaders.